Mannkind Stock Price, News & Analysis

MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $18.9 million for Q2 2022, a 28% increase year-over-year, driven by Afrezza net revenue of $10.6 million. The FDA approved Tyvaso DPI, contributing to revenue recognition. However, collaborations revenue decreased by $7.4 million compared to Q2 2021. The net loss decreased to $29.0 million, or $0.11 per share, from $35.5 million, aided by improved gross profit margins. Expenses rose due to heightened promotional efforts for Afrezza and V-Go.

MannKind Corporation (Nasdaq: MNKD) will announce its 2022 second-quarter financial results on August 9, 2022, at 5:00 PM Eastern Time. CEO Michael Castagna and CFO Steven Binder will lead a conference call to discuss these results and the company's updates. MannKind focuses on developing innovative therapies, particularly for conditions like diabetes and pulmonary arterial hypertension, leveraging its specialized dry-powder delivery technology. Investors can access the live call through the company’s website for detailed insights on performance and strategy.

MannKind Corporation (Nasdaq: MNKD) announced its participation in the BTIG Biotechnology Conference on August 8-9, 2022. CEO Michael Castagna and CFO Steven Binder will engage in one-on-one meetings during this event, aimed at institutional investors.

BTIG specializes in various financial services and hosts client events across multiple sectors. MannKind is known for its innovative products for endocrine and lung diseases, notably Afrezza (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting insulin approved in the U.S. This participation highlights MannKind’s ongoing commitment to advancing its therapeutic portfolio.

MannKind Corporation (Nasdaq: MNKD) is set to showcase its innovative diabetes solutions at the American Diabetes Association’s 82nd Scientific Sessions in New Orleans from June 3-7, 2022. Highlighting its commitment to diabetes care, the company will feature products like Afrezza® and V-Go®. MannKind will host a booth (#1019) to engage healthcare professionals and present an abstract on Technosphere® Insulin. Additionally, a Product Theater event on ultra-rapid inhaled insulin will take place on June 4 at 4:30 p.m. (ET) with featured experts.

MannKind Corporation (Nasdaq: MNKD) announced FDA approval for United Therapeutics' Tyvaso DPI (treprostinil) inhalation powder, marking it as the first dry powder treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Manufacturing is commencing at MannKind's Connecticut facility, with availability expected in June 2022. This marks the second FDA approval utilizing MannKind’s Technosphere inhalation technology, promoting convenience and improved health management for patients.

MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will ring the opening bell at Nasdaq on May 23, 2022, at 9:30 am ET. The ceremony is part of a promotional event to highlight the company's focus on inhaled therapeutic products for endocrine and orphan lung diseases. MannKind's flagship product, Afrezza, is the only FDA-approved inhaled ultra-rapid acting mealtime insulin in the U.S. and is also available in Brazil through its partner, Biomm SA. This event reflects the company’s commitment to bringing innovative treatments to market.

MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of the V-Go insulin delivery device from Zealand Pharma A/S for $10 million, plus sales-based milestones. This acquisition aims to enhance MannKind's portfolio of innovative diabetes solutions, reinforcing its commitment to mealtime diabetes management. The deal is expected to close in May 2022, subject to certain conditions. The V-Go device, designed for ease of use, complements MannKind's existing product, Afrezza, positioning the company for potential growth in the diabetes market.

MannKind Corporation (Nasdaq: MNKD) announced its participation in upcoming healthcare conferences, featuring CEO Michael Castagna as a presenter. Key events include the 2022 RBC Capital Markets Global Healthcare Conference on May 17 at 11:00 am ET, and the H.C. Wainwright Global Investment Conference on May 24 at 1:30 pm ET. Live webcasts of the presentations can be accessed via the Company’s website, with replays available for 14 days post-event. MannKind focuses on inhaled therapeutic products, notably Afrezza®, the first FDA-approved inhaled mealtime insulin in the U.S.

MannKind Corporation (Nasdaq: MNKD) reported Q1 2022 financial results with Afrezza net revenue of $9.8 million, reflecting a 21% increase from Q1 2021. The company's gross profit rose 99% to $7.5 million, supported by a 77% gross margin. Total revenues were $12.0 million, impacted by a $7.2 million drop in collaborations and services revenue due to completed R&D services with United Therapeutics. Net loss grew to $26.0 million, or $0.10 per share, attributed to reduced collaboration revenue and increased costs. Cash reserves stood at $233.0 million as of March 31, 2022.